Commentary by Melissa Freeman, PGY-2
As summertime is just around the corner, many begin to evaluate whether their bodies are ready to expose what has been hidden under those bulky winter clothes. Between busy lives …
Category: Pharmacology
Clinical Correlations
Class Act: The Polypill Panacea
May 1, 2008
Commentary by David Hatcher, MSIII (reviewed by Neil Shapiro, MD Editor-In-Chief, Clinical Correlations)
C.M. is a 68 year-old retired Caucasian male with a past medical history significant for coronary artery disease, hyperlipidemia, HTN, …
Future Medicine: The Search for a New Anticoagulant
April 16, 2008
Future Medicine is a new section of Clinical Correlations devoted to hot areas of research and development in various fields of medicine. In tihis series, we will highlight treatments in their infancy, from basic research opening up …
Class Act: Do Statins Always Have to Be Taken in the Evening?
January 10, 2008
Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. These posts focus on evidenced based answers to clinical questions related to patients seen by our students in …
Clinical Question: Pharmacology
December 28, 2007
Is there evidence to support the use of Lantus® (human insulin analog glargine) administered Q12h in Type 1 Diabetes?
Commentary by Kathy Lee, Pharmacy Resident
The goal of diabetes management is to reduce the risk …
FDA Warns of Possible Link Between Chantix Therapy and Mood Disturbances
December 14, 2007
Commentary by Robert Leonard PharmD, Pharmacy Resident New York Harbor Healthcare System
On November 20, 2007 the FDA announced mounting evidence linking varenicline (Chantix®) therapy for smoking cessation with suicidal ideation and erratic and aggressive behavior. …
FDA Approves Raltegravir- A First in New Class of HIV Medications
November 14, 2007
Commentary by Helen Kourlas PharmD, Pharmacology Section Editor
On October 16th the FDA announced the approval of raltegravir (Isentress®) for the treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents. The use …
FDA Approves Label Revision for Erectile Dysfunction Drugs
October 24, 2007
Commentary by Kathy Lee, Pharm.D. Pharmacy Practice Resident
On October 18 2007, the FDA announced the approval of labeling changes to erectile dysfunction (ED) drugs in the class known as phosphodiesterase type 5 (PDE-5) inhibitors. This …